Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
about
Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell TypesImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteHigh efficiency cell-specific targeting of cytokine activityA comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancerTargeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer.Using antibodies to target cancer therapeutics.Designing immunoconjugates for cancer therapy.Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids.The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate.Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model.The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease.A Monoclonal Antibody to Human DLK1 Reveals Differential Expression in Cancer and Absence in Healthy TissuesEmerging classes of armed antibody therapeutics against cancerA Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy
P2860
Q21131160-D8D33788-FF80-41C4-B58A-9D6D830C606EQ28066935-FF5DA4AC-F448-454B-809D-1A8038F0B32FQ28305410-E05A0C26-8470-4F68-945E-AE0D0D481937Q35027232-5B633195-63DD-49F6-9570-ECC8D59ABA3BQ36127898-20ACFAFE-2C89-4148-A3C1-12864F2E8B8EQ37485709-716DCD05-4DFA-45E9-8AB7-1252BEA0109BQ37593714-1D7438FD-8142-4EAE-8E07-F1FD14ECE72BQ38014920-C0860A8C-FBB4-4458-B165-884066BEE6E2Q38017203-66F180A3-6E6D-48FF-AB64-464776F9714FQ38032893-0C759159-7BE2-4B19-9F2C-EF09410B0D7BQ38873741-A56B49B1-E751-4B06-89FA-DFF60A18CFB7Q38905573-56E83FE6-177D-448F-BF0B-3B3581319DA1Q38998638-6DD315BC-FDD9-4B1E-81CD-323C3369A9EBQ39100229-2519A3A1-F703-4066-8957-2541477F5B5FQ39185087-E7F68A06-C1DB-469B-9989-696960478C42Q39205186-0A4404DA-4CEA-4283-AB34-A0274AB17103Q39448373-9A35BF27-FEA0-4AD7-B108-66D66784F16FQ49687675-A1354BC3-CD99-418D-8838-6A170543702CQ50592781-8B4BE9B4-6FDE-46FE-B143-91478EED10FDQ50864449-E94B5B6F-1D18-4135-8E0E-BC25AE9272E4Q51786117-37FB8214-5848-4056-8A75-0402DCDC9004Q53499740-85386C96-1841-4F92-A1D9-7C98EC63665AQ57911915-250B052F-BF82-4E88-881A-3E989DC90098Q57911948-5339545B-7756-4C5F-84D3-D91B02C68CAAQ57911965-1DFDD529-35A2-47DB-B426-434D15CEE2DE
P2860
Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Antibody-based targeting of in ...... lature: a critical evaluation.
@en
Antibody-based targeting of in ...... lature: a critical evaluation.
@nl
type
label
Antibody-based targeting of in ...... lature: a critical evaluation.
@en
Antibody-based targeting of in ...... lature: a critical evaluation.
@nl
prefLabel
Antibody-based targeting of in ...... lature: a critical evaluation.
@en
Antibody-based targeting of in ...... lature: a critical evaluation.
@nl
P2093
P2860
P356
P1433
P1476
Antibody-based targeting of in ...... lature: a critical evaluation.
@en
P2093
Andjelija Zivanovic
Katharina Frey
Kathrin Schwager
P2860
P304
P356
10.1039/C0IB00099J
P50
P577
2011-01-11T00:00:00Z